November 2024 – Page 21 – Get News Story

WDLS ATHENA at the United Nations to Make History during Women’s History Month

UWG Global Reflections is proud to announce the 20th Anniversary of the World Diversity Leadership Summit (WDLS) ATHENA, taking place at the United Nations Headquarters, Delegates Room in New York City on March 25-26, 2025. This will be the first time that the conference will be held during Women’s History month, and within the Women’s history UN event calendar. Janet Salazar, WDLS Athenastrategic partner stated “The WDLS Athena’s 20 years of excellence is nowaccomplishing another great milestone, by holding the event during Women’s history month.”

The event was first held in Prague Czech Republic in December 2004. Over 3,000 leaders have participated including the CEOs of Aviva, HSBC, Adecco, MGM, Arrow Electronics, Sovereign Bank (now Santander), Bud Selig former Commissioner of Major League Baseball and Secretary of State Hillary Clinton. This edition will bring together up to 300 global leaders, corporate executives, and policymakers to discuss the advancement of women in leadership roles across various sectors.

The WDLS ATHENA is dedicated to empowering women and driving inclusive growth in fields such as Artificial Intelligence, global politics, entrepreneurship, and financial markets. This year’s summit will feature keynote speeches, panel discussions, and workshops designed to foster innovative solutions and collaborative strategies for gender equity in leadership.

One of the highlights of the summit is the inaugural Athenas Awards Luncheon, where exceptional women leaders will be honored for their significant contributions to their industries and communities. Nominations are currently open, encouraging organizations and individuals to recognize women who have made a meaningful impact in advancing diversity and inclusion.

https://www.uwgglobalreflections.org/nominate

“We are thrilled to celebrate two decades of leadership and commitment to diversity with WDLS ATHENA. This summit is a testament to the strides women have made in breaking barriers and setting new standards in leadership,” said Douglas C. Freeman, President of UWG Global Reflections and Founder of the WDLS. “Our goal is to continue inspiring and equipping the next generation of women leaders with the tools and networks they need to succeed.”

As the world continues to grapple with the challenges of gender disparity, events like WDLS ATHENA play a crucial role in highlighting the importance of diverse representation in decision-making positions. UWG Global Reflections is committed to partnering with organizations worldwide to implement DEI (Diversity, Equity, and Inclusion) strategies that not only transform businesses but also contribute to a more equitable society.

To learn more about WDLS ATHENA, register for the event, or submit a nomination for the WDLSAthenas Awards, please visit https://www.uwgglobalreflections.org/nominate

About UWG Global Reflections

UWG Global Reflections, a division of UniWorld Group, specializes in integrating diversity, equity, and inclusion into business strategies. With over 150 years of collective experience, the organization works with global entities to create inclusive corporate cultures and foster sustainable growth through innovative DEI solutions.

Media Contact
Company Name: UWG Global Reflections
Contact Person: Lisa Giamo
Email: Send Email
Phone: 917-858-9090
State: New York
Country: United States
Website: https://www.uwgglobalreflections.org/wdls-athena

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: WDLS ATHENA at the United Nations to Make History during Women’s History Month

SLKOR new partner AXE Components Limited

We are extremely excited to announce that AXE Components Limited has become an official distributor of SLKOR.

In the face of the rapidly changing international market environment and the increasingly fierce competitive situation, SLKOR always maintains a humble, open, cooperative and sharing attitude. Actively absorbing others’ rich experience, different ideas and keeping up with the times, it insists on continuously improving and exploring its own internationalization path. For this reason, SLKOR launched a new agent plan in 2024, increasing the opportunity to cooperate with partners with rich overseas sales experience, and striving to take a new step in its own development in the international market.

On October 25, 2024, Qiu Huilin, director of the foreign trade department of SLKOR, visited AXE components limited. Luo Ronglong, the founder, represented AXE components limited and accepted the SLKOR agency certificate, marking the official launch of the cooperation strategy between the two parties. In the following process, Mr. Luo Ronglong shared his unique insights and experiences accumulated over the years in the field of semiconductor foreign trade sales, providing inspiration and a new direction for the SLKOR foreign trade team!

SLKOR Qiu Huilin and AXE components limited boss

AXE components limited is a young team. The founder is a young person born in the 1990s. Their slogan is as fresh and powerful as the company’s name: Boost human technology and travel around the universe and stars! Since the company was founded until now, they are committed to serving large European, American OEM, EMS, and CEM terminal customers. They mainly sell and purchase brand new original chips, and provide customers with one-stop supporting services such as sales, procurement, quality control, warehousing, and logistics to secure the supply chain for global terminal customers.

AXE components limited office

Since the establishment of Shenzhen SLKOR Micro Semicon Co., Ltd., Mr. Song Shiqiang, the general manager, has been striding towards the international market with firm steps. In the past two years, the foreign trade team of SLKOR has achieved some results in promotion and sales. For example, SLKOR products have been officially launched on the global electronic component online platform – DigiKey Electronics, and have obtained international product quality certificates such as EU RoHS, REACH, and California Proposition 65. For the foreign trade team still in the exploration stage, achieving these results is a great encouragement, prompting them to take every step in the future more solidly and confidently.

Training at SLKOR headquarters

In terms of products, the brand “SLKOR” has international popularity and reputation. The products cover three major series: diodes, transistors, power devices, and power management chips. There are also new products such as Hall sensors, ADCs, BMS, sensors, high-speed optocouplers, and passive crystal oscillators. They are widely used in industries such as smartphones, laptops, robots, power tools, the Internet of Vehicles, 3C digital products, and the Internet of Everything.

For SLKOR and AXE components limited, this cooperation is not just a simple product agency relationship, but also a deep strategic cooperation. It is also based on the common goal of both parties that one plus one is greater than two. During this visit to AXE components limited, Mr. Luo Ronglong, the founder, also revealed in his words that they are intensively preparing for the upcoming international electronics exhibition held in Munich, Germany, and will bring SLKOR’s product brochures to the exhibition. As a top event in the global electronics industry, the Munich International Electronics Exhibition brings together top enterprises and innovative products from all over the world. For any semiconductor enterprise, being able to showcase its products on this stage is a rare opportunity. And SLKOR is fortunate to have a place in AXE components limited’s booth, which is undoubtedly the best proof of SLKOR’s quality and market competitiveness.

According to Mr. Song Shiqiang, the founder of Kinghelm and SLKOR, he looks forward to the cooperation between SLKOR and AXE components limited bringing new development opportunities in the future. Both parties will also jointly explore the international market and meet the diverse needs of global customers with better products and services, and strive to carve out a small place of their own in the international market. SLKOR also wishes AXE components limited a brilliant and triumphant return at electronica 2024 Munich German in advance.

Media Contact
Company Name: Shenzhen SLKOR Micro Semicon Co., Ltd.
Contact Person: Support
Email: Send Email
Phone: +86 13008868302
Address:2010, Block A, Bairuida Building Vanke City Community Bantian Avenue, Longgang District
City: Shenzhen
Country: China
Website: www.slkoric.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SLKOR new partner AXE Components Limited

Norbert G. Gomes’s Ireland’s Unparalleled Essence Vol. 1-5 Invites Readers Into the Rich Tapestry of Ireland’s Landscapes and Legends

Through skillful poetic storytelling, celebrated author Norbert G. Gomes unravels Ireland’s vivid history, guiding readers through the country’s diverse regions and unveiling the intrinsic beauty entrenched within its ancient castles and serene countryside. Combining poetry, travel, memoir and historical book genres, this one-of-a-kind collection weaves together Ireland’s past and present, painting a mesmerizing portrait of the country’s very essence.

Recognized by Marquis Who’s Who for his lifetime accomplishments, Norbert G. Gomes stands as a beacon of scholarly and creative achievement.

He led a distinguished career in radio broadcasting, notably creating and launching TEN-Q Radio in Los Angeles. In addition, his innovative spirit extends to his ventures in orchid breeding, having registered nearly 600 new cymbidium hybrid orchids and discovering new species during an expedition in Asia.

A true creative visionary, Gomes’ passion extends to storytelling and music. His golden ear for hit music has earned him over 70 Gold and Platinum record awards. He has also written five books designed to reveal the profound beauty and history of Ireland. This one-on-one interview shares Norbert G Gomes’s background and experience writing Ireland’s Unparalleled Essence Vol. 1-5.

Tell us about Ireland’s Unparalleled Essence Vol. 1-5.

In this celebration of Irish heritage, Ireland’s Unparalleled Essence Vol. 1-5 not only showcases the physical beauty of Ireland but also delves into its cultural identity, mythology, literature, and history.

Readers will experience the mysticism of Ireland’s historic landscapes, the resiliency of Ireland’s tenacious locals, the heart-pounding tunes of traditional Irish music, the passion of the Gaelic games, the dynamism of Ireland’s national identity and more.

Through these books, my goal is to provide readers with a deeper understanding of Ireland’s influence on modern heritage and identity perspectives, highlighting Ireland’s enduring beauty and warmth via the interplay of poetic words and evocative descriptions.

How did your background and experience influence your writing?

I have always had a lifelong admiration for Irish culture—and as the home of my wife’s descendants, my connection to Ireland runs deep.

I have always been committed to exploring and celebrating cultural narratives and my journey as a lifelong scholar and creative professional led me to this defining work.

In addition, my multifaceted career—spanning radio broadcasting, as a syndicated columnist, and in orchid breeding—informs my unique approach to storytelling.

Weaving this fascinating storytelling in poetic form has always come naturally to me and Ireland being the home of endless poetic wordsmiths was a comfortable setting for me to expand on my creative style.

What is one message you would like readers to remember?

The foremost purpose of these books are to: ENGAGE EVERY READER!

Transcending the typical travel guide, these books offer readers an immersive experience, appealing to anyone intrigued by Ireland’s history, nature, and cultural legacy. Ultimately, this collection is an exploration of Ireland’s spirit, designed to captivate a broad audience.

Purchasing the Book

Ireland’s Unparalleled Essence Vol. 1-5 has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Book Excellence writes, “Gomes’ literary prowess shines through in this detailed and exceptional collection showcasing Ireland’s heart and soul. Written in rich poetic form, these books are true gems for anyone interested in learning more about Ireland’s history, folklore and landscapes.”

The books are available for sale on Amazon, Barnes & Noble, Kobo, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/stores/Norbert-G-Gomes/author/B0CRGCQPZ8

To connect with Norbert and learn more about his work, visit: https://www.norbertgomes.com. You can also find him on Facebook, YouTube and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Norbert G. Gomes’s Ireland’s Unparalleled Essence Vol. 1-5 Invites Readers Into the Rich Tapestry of Ireland’s Landscapes and Legends

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal

The Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, and others.

DelveInsight’s “Non-Alcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Alcoholic Steatohepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Steatohepatitis Market Forecast

Some of the key facts of the Non-Alcoholic Steatohepatitis Market Report:

Among the 7MM countries Non-Alcoholic Steatohepatitis market size was valued approximately USD 1,634 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In July 2024, Inventiva has provided updates on its Phase III NATiV3 clinical program evaluating lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH). The recruitment process for the trial is currently ongoing at 347 sites in 19 countries.
DelveInsight’s analysis in 2022 indicated approximately 41,885,455 prevalent cases of Non-Alcoholic Steatohepatitis (NASH) across the 7MM (Seven Major Markets). Among them, 15,620,949 cases were diagnosed. These figures are expected to rise by 2032 across the 7MM.
In 2022, the United States reported the highest number of diagnosed prevalent cases of Non-Alcoholic Steatohepatitis (NASH), totaling 9,389,584 cases. In comparison, the EU4 countries and the UK had 3,674,346 cases, and Japan had 2,557,019 cases.
In the European region, Germany reported the highest diagnosed prevalence of Non-Alcoholic Steatohepatitis (NASH) with 965,439 cases, followed by Italy with 783,811 cases in 2022. Conversely, Spain had the lowest diagnosed prevalent population among the EU4 countries and the UK, with 549,113 cases.
The existing pipeline for Non-Alcoholic Steatohepatitis (NASH) comprises a diverse array of medications. Notable classes include FXR Agonists, FGF21 Stimulants, FGF19 Analog, Glucagon-like Peptide-1 (GLP-1) Agonist, Peroxisome Proliferator-activated Receptor (PPAR) Regulator, THR-β Agonist, and others. Ongoing research and ongoing clinical trials hold the promise of reshaping the market landscape for NASH treatment.
Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
The Non-Alcoholic Steatohepatitis epidemiology based on gender analyzed that males have a slightly higher likelihood of being affected by NASH compared to females in the 7MM.
The Non-Alcoholic Steatohepatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Steatohepatitis pipeline products will significantly revolutionize the Non-Alcoholic Steatohepatitis market dynamics.

Non-Alcoholic Steatohepatitis Overview

Non-Alcoholic Steatohepatitis (NASH) is a liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage, resembling alcoholic liver disease but occurring in individuals who consume little to no alcohol. NASH is considered a severe form of non-alcoholic fatty liver disease (NAFLD) and can lead to complications such as cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

Get a Free sample for the Non-Alcoholic Steatohepatitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market

Non-Alcoholic Steatohepatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Alcoholic Steatohepatitis Epidemiology Segmentation:

The Non-Alcoholic Steatohepatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Non-Alcoholic Steatohepatitis
Prevalent Cases of Non-Alcoholic Steatohepatitis by severity
Gender-specific Prevalence of Non-Alcoholic Steatohepatitis
Diagnosed Cases of Episodic and Chronic Non-Alcoholic Steatohepatitis

Download the report to understand which factors are driving Non-Alcoholic Steatohepatitis epidemiology trends @ Non-Alcoholic Steatohepatitis Epidemiology Forecast

Non-Alcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Non-Alcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Alcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Steatohepatitis Therapies and Key Companies

Lanifibranor: Inventiva Pharma
Saroglitazar Magnesium: Zydus Therapeutics
Semaglutide: Novo Nordisk A/S
VK2809: Viking Therapeutics
MGL-3196: Madrigal Pharmaceuticals, Inc
HPG1860: Hepagene
Vonafexor (EYP001): Enyo Pharma
Belapectin: Galectin Therapeutics Inc.
Pegozafermin: 89bio, Inc.
Efruxifermin (EFX): Akero Therapeutics, Inc
DA-1241: NeuroBo Pharmaceuticals Inc
NNC0194: Novo Nordisk A/S
J2H-1702: J2H Biotech
HSK31679: Haisco Pharmaceutical
Pemvidutide: Altimmune, Inc.
AZD9550: AstraZeneca
Survodutide: Boehringer Ingelheim
Namodenoson: Can-Fite BioPharma
Resmetirom: Madrigal Pharmaceuticals
GSK4532990: GlaxoSmithKline
BIO89-100: 89bio, Inc.
EFX: Akero Therapeutics, Inc
ALN-HSD: Regeneron Pharmaceuticals
HPG1860: Hepagene (Shanghai) Co., Ltd.
IVA337: Inventiva Pharma
HM15211: Hanmi Pharmaceutical
VK2809: Viking Therapeutics, Inc.
MGL-3196: Madrigal Pharmaceuticals, Inc.
SNP-610: Sinew Pharma Inc.
BOS-580: Boston Pharmaceuticals

Discover more about therapies set to grab major Non-Alcoholic Steatohepatitis market share @ Non-Alcoholic Steatohepatitis Treatment Landscape

Non-Alcoholic Steatohepatitis Market Strengths

Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed that will strengthen the market.

Non-Alcoholic Steatohepatitis Market Opportunities

The large pool of patients suffering from NASH and lucrative opportunities for market growth create attractive prospects for key players to work in these areas

Scope of the Non-Alcoholic Steatohepatitis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Non-Alcoholic Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Non-Alcoholic Steatohepatitis Market Access and Reimbursement

To know more about Non-Alcoholic Steatohepatitis companies working in the treatment market, visit @ Non-Alcoholic Steatohepatitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Non-Alcoholic Steatohepatitis Market Report Introduction

2. Executive Summary for Non-Alcoholic Steatohepatitis

3. SWOT analysis of Non-Alcoholic Steatohepatitis

4. Non-Alcoholic Steatohepatitis Patient Share (%) Overview at a Glance

5. Non-Alcoholic Steatohepatitis Market Overview at a Glance

6. Non-Alcoholic Steatohepatitis Disease Background and Overview

7. Non-Alcoholic Steatohepatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Alcoholic Steatohepatitis

9. Non-Alcoholic Steatohepatitis Current Treatment and Medical Practices

10. Non-Alcoholic Steatohepatitis Unmet Needs

11. Non-Alcoholic Steatohepatitis Emerging Therapies

12. Non-Alcoholic Steatohepatitis Market Outlook

13. Country-Wise Non-Alcoholic Steatohepatitis Market Analysis (2019–2032)

14. Non-Alcoholic Steatohepatitis Market Access and Reimbursement of Therapies

15. Non-Alcoholic Steatohepatitis Market Drivers

16. Non-Alcoholic Steatohepatitis Market Barriers

17. Non-Alcoholic Steatohepatitis Appendix

18. Non-Alcoholic Steatohepatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics

The Key Vascular Ehlers-Danlos Syndrome Companies in the market include – Aytu BioPharma, Acer Therapeutics, and others.

The Vascular Ehlers-Danlos Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vascular Ehlers-Danlos Syndrome pipeline products will significantly revolutionize the Vascular Ehlers-Danlos Syndrome market dynamics.

DelveInsight’s “Vascular Ehlers-Danlos Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vascular Ehlers-Danlos Syndrome, historical and forecasted epidemiology as well as the Vascular Ehlers-Danlos Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Vascular Ehlers-Danlos Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Vascular Ehlers-Danlos Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vascular Ehlers-Danlos Syndrome Market Insights

Some of the key facts of the Vascular Ehlers-Danlos Syndrome Market Report:

The Vascular Ehlers-Danlos Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
According to the VEDS Movement (n.d.), the exact number of affected people with Vascular Ehlers-Danlos Syndrome is not known
According to a news article published by Ehlers-Danlos Support United Kingdom, the prevalence of EDS is generally quoted as 1 in 5000. Seventy percent of the individuals with EDS or JHS are female and thirty percent are male.
Key Vascular Ehlers-Danlos Syndrome Companies: Aytu BioPharma, Acer Therapeutics, and others
Key Vascular Ehlers-Danlos Syndrome Therapies: AR101 (enzastaurin), Edsivo, and others
The Vascular Ehlers-Danlos Syndrome epidemiology based on gender analyzed that among all hospitalized and GP practice EDS patients, approximately 70% were females

Vascular Ehlers-Danlos Syndrome Overview

Vascular Ehlers-Danlos Syndrome (vEDS) is a genetic connective tissue disorder characterized by fragile blood vessels, leading to a heightened risk of arterial and organ rupture. It is caused by mutations in the COL3A1 gene, which is essential for producing type III collagen, a key component of connective tissue. Individuals with vEDS often present with symptoms such as thin, translucent skin, easy bruising, and joint hypermobility. The condition can result in serious complications, including life-threatening vascular events. Management focuses on preventive measures, careful monitoring, and prompt treatment of complications to improve outcomes and quality of life for affected individuals.

Get a Free sample for the Vascular Ehlers-Danlos Syndrome Market Report-

https://www.delveinsight.com/report-store/vascular-ehlers-danlos-syndrome-veds-market

Vascular Ehlers-Danlos Syndrome Epidemiology

Vascular Ehlers-Danlos Syndrome Epidemiology Segmentation:

The Vascular Ehlers-Danlos Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Vascular Ehlers-Danlos Syndrome
Prevalent Cases of Vascular Ehlers-Danlos Syndrome by severity
Gender-specific Prevalence of Vascular Ehlers-Danlos Syndrome
Diagnosed Cases of Episodic and Chronic Vascular Ehlers-Danlos Syndrome

Vascular Ehlers-Danlos Syndrome Market

The dynamics of the Vascular Ehlers-Danlos Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The emerging pipeline for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS) has two therapies AR101 (enzastaurin) and Edsivo. A very few candidates are being investigated by pharmaceuticals companies in this disease area”

Download the report to understand which factors are driving Vascular Ehlers-Danlos Syndrome epidemiology trends @ Vascular Ehlers-Danlos Syndrome Epidemiological Insights

Vascular Ehlers-Danlos Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vascular Ehlers-Danlos Syndrome market or expected to get launched during the study period. The analysis covers Vascular Ehlers-Danlos Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Vascular Ehlers-Danlos Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Vascular Ehlers-Danlos Syndrome Therapies and Key Companies

AR101 (enzastaurin): Aytu BioPharma
Edsivo: Acer Therapeutics

To know more about Vascular Ehlers-Danlos Syndrome treatment, visit @ Vascular Ehlers-Danlos Syndrome Medications

Scope of the Vascular Ehlers-Danlos Syndrome Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Vascular Ehlers-Danlos Syndrome Companies: Aytu BioPharma, Acer Therapeutics, and others
Key Vascular Ehlers-Danlos Syndrome Therapies: AR101 (enzastaurin), Edsivo, and others
Vascular Ehlers-Danlos Syndrome Therapeutic Assessment: Vascular Ehlers-Danlos Syndrome current marketed and Vascular Ehlers-Danlos Syndrome emerging therapies
Vascular Ehlers-Danlos Syndrome Market Dynamics: Vascular Ehlers-Danlos Syndrome market drivers and Vascular Ehlers-Danlos Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Vascular Ehlers-Danlos Syndrome Unmet Needs, KOL’s views, Analyst’s views, Vascular Ehlers-Danlos Syndrome Market Access and Reimbursement

Discover more about therapies set to grab major Vascular Ehlers-Danlos Syndrome market share @ Vascular Ehlers-Danlos Syndrome Treatment Landscape

Table of Contents

1. Vascular Ehlers-Danlos Syndrome Market Report Introduction

2. Executive Summary for Vascular Ehlers-Danlos Syndrome

3. SWOT analysis of Vascular Ehlers-Danlos Syndrome

4. Vascular Ehlers-Danlos Syndrome Patient Share (%) Overview at a Glance

5. Vascular Ehlers-Danlos Syndrome Market Overview at a Glance

6. Vascular Ehlers-Danlos Syndrome Disease Background and Overview

7. Vascular Ehlers-Danlos Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Vascular Ehlers-Danlos Syndrome

9. Vascular Ehlers-Danlos Syndrome Current Treatment and Medical Practices

10. Vascular Ehlers-Danlos Syndrome Unmet Needs

11. Vascular Ehlers-Danlos Syndrome Emerging Therapies

12. Vascular Ehlers-Danlos Syndrome Market Outlook

13. Country-Wise Vascular Ehlers-Danlos Syndrome Market Analysis (2019–2032)

14. Vascular Ehlers-Danlos Syndrome Market Access and Reimbursement of Therapies

15. Vascular Ehlers-Danlos Syndrome Market Drivers

16. Vascular Ehlers-Danlos Syndrome Market Barriers

17. Vascular Ehlers-Danlos Syndrome Appendix

18. Vascular Ehlers-Danlos Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics

The Sultanate of Gowa Forged an Alliance with the Sultanate of Magindanaw and We Care for Humanity

“(L-R) HM Andi Kumala Idjo Malikusaid, HM Sultan Sulkarnain Mastura Kudarat VI, HRH Queen Mariam Leonor Torres Mastura, HM Andi Hikmawati Kumala”

Successful WCH-Magindanaw Royal Tour led to partnerships and collaborations of We Care for Humanity, Sultanate of Magindanaw and Sultanate of Gowa.

11 Nov, 2024 – Gowa Makassar – The fifth enchanting stop on the WCH-Magindanaw Royal Tour led to the illustrious Sultanate of Gowa. This official visit commenced with a journey to the royal abode of His Majesty Andi Kumala Idjo Karaeng Lembang Parang Sultan Malikusaid, the esteemed Sultan of Gowa ke XXXVIII.

Upon their arrival, the Magindanaw royals; HM Sultan Sulkarnain Mastura Kudarat VI, the 26th Supreme Sultan of Mahindanaw and HRH Queen Mariam Leonor Torres Mastura, the Maha Putri of the Royal House of Luzon Tagalog and founder of We Care for Humanity, were greeted with a traditional welcome beneath an ornate royal canopy held by vigilant guards, accompanied by a mesmerizing warrior dance performed upon a crimson carpet. The air was filled with the harmonious melodies of traditional Gowa music, played by skilled musicians who seemed to weave magic with their instruments.

Royals from both Sultanates mingled, exchanging stories and laughter, their conversations a testament to the vibrant cultural exchange that was unfolding. In her message, Queen Mariam highlighted that the purpose of the royal tour is to promote cultural exchange and establish meaningful, peaceful alliances between traditional kingdoms, as well as to advocate for peace and unity. She also noted that We Care for Humanity is always prepared to assist with social activities, particularly for the underprivileged individuals of the Sultanate of Gowa.

Video Link: https://www.youtube.com/embed/mSsUKJCV7OI

A poignant highlight of this visit was the bestowal of the “Greatest Humanitarians of the World” award upon Sultan Idjo and his Queen, Andi Hikmawati Kumala. In a gesture of mutual respect, they honored the Sultan of Magindanaw with a traditional Gowa hat, while the Queen of Maharlika received a distinguished Gowa medal and badge. Thus, the two Sultanates fortified their bond of friendship and brotherhood with a heartfelt embrace and the signing of a Letter of Intent, paving the way for a Memorandum of Understanding.

The morning event concluded with a lavish royal luncheon. The hospitality of Gowa was truly evident, thanks to the Gowa monarchs’ attentive care for their royal guests. The dining table was adorned with delectable dishes, accompanied by engaging discussions steeped in history.

The afternoon unfolded with an exhilarating exploration of the Gowa Sultanate’s regal palace and museum, while the evening gracefully concluded with an exquisite dinner hosted by the Regional Secretary of South Sulawesi, the Honorable Dr. Jufri Rahman.

As the night drew to a close, the bonds between the two Sultanates had grown even stronger, fortified by mutual respect and shared aspirations. With promises of continued collaboration and support, the Magindanaw royals departed, leaving behind a legacy of goodwill and a promise of brighter days ahead.

For more photos and videos, visit here.

Media Contact
Company Name: ROYAL MAHARLIKA
Contact Person: RM Admin
Email: Send Email
Phone: 8185145756
Country: Philippines
Website: http://www.royalmaharlika.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Sultanate of Gowa Forged an Alliance with the Sultanate of Magindanaw and We Care for Humanity

QJMOTOR Showcases SRK1000 and Full Lineup at EICMA, Shining with Technological Confidence

At the 2024 EICMA, a leading global two-wheeler trend, top motorcycle brand QJMOTOR made a strong appearance in Milan, becoming one of the biggest highlights of the event. Through the release of multiple flagship new models such as SRK1000, SFA 1000, and SFU 1000R, as well as the impressive lineup of over 60 motorcycles on site, QJMOTOR fully demonstrated its powerful scientific and technological manufacturing strength in “building motorcycles for the world”!

With a Global Perspective, QJMOTOR Showcases Internationally Leading Strength

At this EICMA, QJMOTOR’s 1,600 square meter booth was crowded with visitors, and there was a constant stream of audience members inquiring, photographing, and live streaming, showcasing its global influence.

As a leader in the motorcycle industry, QJMOTOR relies on its deep manufacturing heritage and integration with international cutting-edge technology, and is committed to becoming a pioneer in the global riding field. The brand fully absorbs advanced international motorcycle manufacturing technologies and experiences, combines them with its own innovative strength, and creates high-end, intelligent, and personalized motorcycle products for global consumers.

As one of the leading enterprises in China’s motorcycle industry, QJMOTOR Motorcycle is backed by Geely Technology Group. In May 2020, it launched its high-end motorcycle brand – QJMOTOR. Relying on QJMOTOR Motorcycle’s 35 years of manufacturing experience and fully absorbing the motorcycle manufacturing technology and experience of the century-old Italian motorcycle company BENELLI, QJMOTOR aims to become a global leader in the riding field, committed to creating high-end, intelligent, and personalized products, making motorcycles for the world with the hard power of technological innovation.

At this exhibition, QJMOTOR confidently showcased its full range of new products to the world, including over 60 models from its “SRK, SRK RR, SRV, SRT” series of two-wheelers, scooters, electric two-wheelers, and all-terrain vehicles, covering street bikes, sport bikes, adventure bikes, cruisers, scooters, commuters, and electric products, fulfilling the needs of different global travel scenarios and user demands in an overflowing manner, continuously gaining recognition from more global users.

It can be said that whether it’s the scale of participation, the specifications of the exhibition, or the showcasing of its achievements in technological innovation, product manufacturing, and brand globalization, QJMOTOR has demonstrated an unprecedented level of openness and confidence, fully showcasing its strategic ambition to pursue “the world’s leader”.

Fully Armed, Born to Fight: SRK1000 Makes Global Debut

At this exhibition, the SRK1000 liter-class four-cylinder naked bike became the focus of attention. This model is equipped with a 921cc liquid-cooled four-cylinder inline engine re-tuned by the QJMOTOR team, with a maximum power of 120 kW/13600rpm (163 hp) and a maximum torque of 90Nm/11000rpm, delivering strong and smooth output. The motorcycle is equipped with Marzocchi adjustable inverted front suspension, multi-link centrally mounted rear suspension, and Brembo front 320mm dual-disc and rear 260mm single-disc brake system, supplemented by cornering ABS and TCS systems, providing excellent braking performance and safety. The 835mm seat height, 1425mm wheelbase, and ergonomic design bring a comfortable riding experience, while the luxurious configurations such as the 5.5-inch TFT speedometer screen, tire pressure monitoring, and cruise control make it an eye-catching focal point.

The debut of SRK1000 not only enhances the competitive landscape of the global motorcycle market but also demonstrates the strong capabilities of Chinese motorcycle brands to Europe and the world.

QJMOTOR Launches Stunning New All-Terrain Vehicle Products

In addition to SRK1000, QJMOTOR also launched two all-terrain vehicle models, SFA1000 and SFU1000 R.

As a high-performance ATV model, SFA1000 is equipped with a 68kW/7300rpm engine and EPS power-assisted steering system, featuring multi-stage adjustable air suspension, an integrated backrest seat, and a 7-inch TFT large-screen speedometer. While ensuring strong power and excellent off-road performance, it provides high durability and a comfortable driving experience. Its all-terrain tires, 3,500-pound winch, and front and rear trailer ball design make it stable and reliable even in harsh environments, suitable for off-road exploration, outdoor work, and emergency rescue.

The new UTV model SFU1000 R is powered by a twin-cylinder liquid-cooled engine with a maximum power of 65kW/7250rpm and a maximum torque of 95Nm/6250rpm. It is equipped with a 5-inch TFT speedometer, LED headlights, multi-stage adjustable shock absorbers, and other configurations. Coupled with a 392L reversible rear cargo box, it can meet users’ multiple needs and is an ideal choice in the UTV field.

Deeply Cultivating Top-Level Events to Shape Brand Culture, QJMOTOR Accelerates Globalization with an Independent Stance

While making motorcycles for the world, QJMOTOR is also accelerating its brand globalization through multi-dimensional breakthroughs with an independent stance.

With the goal of becoming a global leader in the riding field, QJMOTOR participates in the world’s top WSBK events, putting mass-produced models to the test in fierce top-level competitions. While verifying and improving its products, it also rapidly accumulates motorcycle manufacturing technology experience and gains recognition from a large number of global motorcycle fans and users.

At the same time, QJMOTOR is also actively promoting its overseas localization operation strategy. Based on a thorough understanding of laws and regulations, cultural customs, and user needs, it customizes localized operation strategies and product solutions suitable for each regional market. It strengthens brand building from various aspects such as service systems, product promotion, and social media exposure, and builds a localized QJMOTOR brand culture for different cultural systems, organizing local motorcycle cultural activities to fully showcase the unique charm of Chinese motorcycle brands to motorcycle enthusiasts around the world.

In the context of global mobility transformation, QJMOTOR is fully focusing on global user needs, comprehensively exerting efforts in multiple dimensions such as technological strength, product strength, and brand strength, and accelerating its globalization pace. In the future, QJMOTOR will continue to take the lead in promoting the innovative development of the motorcycle industry and bring more high-quality products and services to global consumers.

Media Contact
Company Name: QJMOTOR
Email: Send Email
Address:No. 169 Jimping Rd. Wenling
City: Taizhou
State: Zhejiang
Country: China
Website: https://global.qjmotor.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: QJMOTOR Showcases SRK1000 and Full Lineup at EICMA, Shining with Technological Confidence

Justin Murta to Drop New Single “Hurt Me” on Black Friday, Blending EDM and R&B in a Unique Fall Sound

Prepare for fall vibes with Justin Murta’s latest single “Hurt Me,” out November 29, fusing Latin House, EDM, and Afrobeats in an atmospheric mix.

Justin Murta, the widely traveled DJ and musician known for his eclectic sound, will soon release his latest single, Hurt Me, featuring the talents of vocalist Atia and produced by JayPDoesit. Available starting Black Friday, November 29, this moody, danceable track combines the fresh beats of EDM, pop, and R&B, layering in Latin and Afrobeats influences to create the perfect anthem for autumn.

Hurt Me follows Murta’s summer single, Hotter Than June, which quickly gained traction, drawing tens of thousands of streams. Collaborating with fellow artist Marty Boombox, Murta introduced fans to his unique sound that pulls from EDM and contemporary pop while incorporating a tropical, live-show energy. Each track on Murta’s nine-song project, which will roll out through 2025, aims to present a fresh yet cohesive sound profile, and Hurt Me is a standout that takes the party vibes of summer and transforms them for a chill yet energizing autumn listen.

Murta, a fixture in the international DJ scene, has shared the stage with major artists like Cee Lo Green, Armin Van Buuren, and Chris Brown. Known for his high-energy live shows and seamless genre-blending, Murta’s sets are a mainstay at festivals, exclusive events, and on tour worldwide. A veteran of the industry with two decades of experience, he has been instrumental in pushing EDM’s boundaries, incorporating everything from K-Pop to hip-hop in his work, all while maintaining an authentic connection with his audience. His upcoming 2025 album release is poised to capture the attention of the dance and EDM world, establishing Murta as a forward-thinking artist with a global following.

Fans can find Hurt Me on Spotify, Apple Music, and other major streaming platforms. Murta will continue to tour through spring 2025, bringing his newest music to audiences across the United States and building anticipation for his album debut.

ABOUT

Justin Murta is an acclaimed American DJ and musician, recognized for his energetic live sets and international tours spanning over 34 countries. Murta started his music journey as a violinist and his career catapulted in Seattle’s hip-hop scene after winning the Seattle Emerging Artist Award. Murta later gained fame in Southeast Asia, headlining festivals and being an ambassador for major brands such as Converse, Heineken and Smirnoff Vodka. In 2020, his debut solo album Fairytale reached the US Top 100 on the Digital Radio Charts and the Top 5 on the Indie Radio Charts. Currently, he is a resident DJ for King 5 News in Seattle and ITV’s The DJ Sessions. Murta’s musical evolution continues with his latest EDM, pop, and R&B fusion singles, including Hurt Me, leading up to his self-titled album release in 2025.

LINKS

Official Website: https://www.justinmurta.com/

Facebook: https://www.facebook.com/justinmurta1/

Instagram: https://www.instagram.com/djjustinmurta

YouTube: https://youtube.com/@justinmurta?si=vIH3EELJX9Z_K4ke

Spotify: https://open.spotify.com/artist/5ILa3CPbsDyqkhzRdQImpq?si=-ngYCemMR1Om0RMCr-l-mg

Media Contact
Company Name: Justin Murta
Contact Person: Redpillrecords
Email: Send Email
Phone: 4253776304
Address:521 Newberg Rd
City: Snohomish
State: Washington
Country: United States
Website: https://www.justinmurta.com/

Papulopustular Rosacea Market to Expand Significantly by 2034, States DelveInsight Report | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer

The Key Papulopustular Rosacea Companies in the market include – Sol-Gel Technologies/ Galderma, CollaGenex Pharmaceuticals, Tarsus Pharmaceuticals, Pfizer, and others.

DelveInsight’s “Papulopustular Rosacea Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Papulopustular Rosacea, historical and forecasted epidemiology as well as the Papulopustular Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Papulopustular Rosacea, offering comprehensive insights into the Papulopustular Rosacea revenue trends, prevalence, and treatment landscape. The report delves into key Papulopustular Rosacea statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Papulopustular Rosacea therapies. Additionally, we cover the landscape of Papulopustular Rosacea clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Papulopustular Rosacea treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Papulopustular Rosacea space.

To Know in detail about the Papulopustular Rosacea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Papulopustular Rosacea Market Forecast

Some of the key facts of the Papulopustular Rosacea Market Report:

The Papulopustular Rosacea market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
Several new drugs for Papulopustular Rosacea are currently in clinical development, focusing on its inflammatory characteristics. Notable candidates include TP-04 from Tarsus Pharmaceuticals and PF-07038124 from Pfizer, among others. These treatments consist of innovative topical formulations aimed at specific inflammatory pathways, as well as systemic medications designed to enhance efficacy and safety.
Key Papulopustular Rosacea Companies: Sol-Gel Technologies/ Galderma, CollaGenex Pharmaceuticals, Tarsus Pharmaceuticals, Pfizer, and others
Key Papulopustular Rosacea Therapies: EPSOLAY (benzoyl peroxide), ORACEA (doxycycline), TP-04, PF-07038124, and others.
The Papulopustular Rosacea market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Papulopustular Rosacea pipeline products will significantly revolutionize the Papulopustular Rosacea market dynamics.
As per the National Rosacea Society, an estimated 415 million people worldwide are affected by rosacea, with around 16 million cases reported in the United States. The prevalence of rosacea in the US is on the rise.
According to our estimates, the prevalence of rosacea in the United Kingdom is approximately 1.65 per 1,000 person-years. However, epidemiological data on rosacea is limited, with reported prevalence rates varying widely, ranging from as low as 0.09% to as high as 22%.
A study investigating the epidemiology of rosacea in the German population found a prevalence rate of 2.3% among a cohort of 90,880 office workers.
Studies indicate that women are more prone to rosacea than men, with approximately 87% of cases occurring in females and 13% in males in Germany. Among rosacea patients, 64% were diagnosed with the erythematotelangiectatic subtype, 36% had the papulopustular subtype, 24% had the phymatous subtype, and 36% had the ocular subtype.

Papulopustular Rosacea Overview

Papulopustular Rosacea is a chronic inflammatory skin condition characterized by redness, swelling, and the presence of small, pus-filled bumps (papules and pustules) primarily on the face. It is a subtype of rosacea and often affects individuals with fair skin. Common symptoms include facial flushing, sensitivity, and a burning or stinging sensation. Triggers for this condition can include sun exposure, hot beverages, spicy foods, stress, and certain skincare products. Treatment typically involves topical or oral medications to reduce inflammation, manage symptoms, and prevent flare-ups.

Get a Free sample for the Papulopustular Rosacea Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/papulopustular-rosacea-market

Papulopustular Rosacea Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Papulopustular Rosacea Epidemiology Segmentation:

The Papulopustular Rosacea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Papulopustular Rosacea
Prevalent Cases of Papulopustular Rosacea by severity
Gender-specific Prevalence of Papulopustular Rosacea
Diagnosed Cases of Episodic and Chronic Papulopustular Rosacea

Download the report to understand which factors are driving Papulopustular Rosacea epidemiology trends @ Papulopustular Rosacea Epidemiology Forecast

Papulopustular Rosacea Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Papulopustular Rosacea market or expected to get launched during the study period. The analysis covers Papulopustular Rosacea market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Papulopustular Rosacea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Papulopustular Rosacea Therapies and Key Companies

EPSOLAY (benzoyl peroxide): Sol-Gel Technologies/ Galderma
ORACEA (doxycycline): CollaGenex Pharmaceuticals
TP-04: Tarsus Pharmaceuticals
PF-07038124: Pfizer

Discover more about therapies set to grab major Papulopustular Rosacea market share @ Papulopustular Rosacea Treatment Landscape

Papulopustular Rosacea Market Drivers

Increasing prevalence of rosacea globally, particularly in developed nations.
Growing awareness about dermatological conditions and their treatment options.
Advancements in the development of targeted therapies, including novel anti-inflammatory drugs.
Availability of a broad range of topical and systemic treatment options.

Papulopustular Rosacea Market Barriers

High cost of advanced therapies and treatments.
Limited availability of curative treatment; therapies mainly manage symptoms.
Side effects associated with long-term use of systemic treatments.
Variability in treatment responses due to individual patient factors.
Lack of comprehensive awareness and diagnosis in developing regions.

Scope of the Papulopustular Rosacea Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Papulopustular Rosacea Companies: Sol-Gel Technologies/ Galderma, CollaGenex Pharmaceuticals, Tarsus Pharmaceuticals, Pfizer, and others
Key Papulopustular Rosacea Therapies: EPSOLAY (benzoyl peroxide), ORACEA (doxycycline), TP-04, PF-07038124, and others
Papulopustular Rosacea Therapeutic Assessment: Papulopustular Rosacea current marketed and Papulopustular Rosacea emerging therapies
Papulopustular Rosacea Market Dynamics: Papulopustular Rosacea market drivers and Papulopustular Rosacea market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Papulopustular Rosacea Unmet Needs, KOL’s views, Analyst’s views, Papulopustular Rosacea Market Access and Reimbursement

To know more about Papulopustular Rosacea companies working in the treatment market, visit @ Papulopustular Rosacea Clinical Trials and Therapeutic Assessment

Table of Contents

1. Papulopustular Rosacea Market Report Introduction

2. Executive Summary for Papulopustular Rosacea

3. SWOT analysis of Papulopustular Rosacea

4. Papulopustular Rosacea Patient Share (%) Overview at a Glance

5. Papulopustular Rosacea Market Overview at a Glance

6. Papulopustular Rosacea Disease Background and Overview

7. Papulopustular Rosacea Epidemiology and Patient Population

8. Country-Specific Patient Population of Papulopustular Rosacea

9. Papulopustular Rosacea Current Treatment and Medical Practices

10. Papulopustular Rosacea Unmet Needs

11. Papulopustular Rosacea Emerging Therapies

12. Papulopustular Rosacea Market Outlook

13. Country-Wise Papulopustular Rosacea Market Analysis (2020–2034)

14. Papulopustular Rosacea Market Access and Reimbursement of Therapies

15. Papulopustular Rosacea Market Drivers

16. Papulopustular Rosacea Market Barriers

17. Papulopustular Rosacea Appendix

18. Papulopustular Rosacea Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Papulopustular Rosacea Market to Expand Significantly by 2034, States DelveInsight Report | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer

In the Shadow of Giants: Unveiling the COO’s Pivotal Role in Business Success

“The Second in Command by Cameron Herold”

Cameron Herold’s New Book Sheds Light on the Unsung Heroes of the Corporate World

Scottsdale, AZ – Nov 5th, 2024 – In a groundbreaking new book, “The Second in Command,” Cameron Herold, host of The Second In Command podcast and also the former COO of 1-800-GOT-JUNK?, unveils the critical yet often overlooked role of Chief Operating Officers in the success of businesses. Drawing from his vast experience, Herold provides a comprehensive guide on the COO’s role, their impact, and how they work in tandem with CEOs to drive business success.

“COOs are the linchpins of an organization, turning the CEO’s vision into a tangible reality,” says Herold. This book is a deep dive into the world of COOs, revealing the intricacies of their work, the challenges they face, and the significant contributions they make behind the scenes.

Through a blend of personal experiences, interviews with top COOs from his podcast “Second In Command,” and insights from the COO Alliance, Herold paints a vivid picture of the dynamic role of COOs. He emphasizes the importance of this key position in companies, especially in times of crisis and significant growth.

This book is an essential read for current and aspiring COOs, CEOs looking to strengthen their leadership team, and anyone interested in the intricate workings of successful corporate management.

“The Second in Command” is now available in bookstores and online platforms.

For more information, interviews, or speaking engagements, contact:

Meridith Kuba VP Operations meridith@cooalliance.com

Cameron Herold – https://cameronherold.com

COO Alliance – https://cooalliance.com/

The Second In Command podcast – https://podcasts.apple.com/us/podcast/second-in-command-the-chief-behind-the-chief/id1368800817

The Second In Command book – https://a.co/d/287lESq

Media Contact
Company Name: COO Alliance
Contact Person: Meridith Kuba
Email: Send Email
Phone: 480-292-1214
Address:4400 N Scottsdale Rd Ste 9-916
City: Scottsdale
State: AZ
Country: United States
Website: www.cooalliance.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In the Shadow of Giants: Unveiling the COO’s Pivotal Role in Business Success